S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children
NCT ID: NCT05243836
Last Updated: 2025-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
441 participants
INTERVENTIONAL
2023-08-04
2028-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Spectacle Films Utilising S.T.O.P.® Technology for Slowing Down Myopia Progression in Children
NCT06137560
An Evaluation of the Effectiveness of Dual Focus Soft Contact Lenses in Slowing Mypoia Progression
NCT01729208
Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.
NCT01917110
Stellest Lenses and Low-concentration Atropine Myopia Control Among Children
NCT06344429
Influence of Rodenstock Spectacle Lenses on Myopia Progression.
NCT06816446
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The visits are Baseline / Fit, Dispensing, 1 week, 1 month, 6 months then visits every 6 months after.
All procedures performed at these visits are standard, non invasive clinical tests.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MiSight®
MiSight® Contact Lens (Omafilcon A, 60% water)
MiSight®
Omafilcon A (60% water)
S.T.O.P® F2
S.T.O.P® F2 Contact Lens (Ocufilcon D, 55% water)
S.T.O.P® F2
Ocufilcon D, 55% water
S.T.O.P® DT
S.T.O.P® DT Contact Lens (Ocufilcon D, 55% water)
S.T.O.P® DT
Ocufilcon D, 55% water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
S.T.O.P® F2
Ocufilcon D, 55% water
S.T.O.P® DT
Ocufilcon D, 55% water
MiSight®
Omafilcon A (60% water)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have:
* Read the Informed Assent.
* Been explained the Informed Assent.
* Indicated an understanding of the Informed Assent.
* Signed the Informed Assent.
* Have their parent / legal guardian:
* Read the Informed Consent.
* Been explained the Informed Consent.
* Indicated an understanding of the Informed Consent.
* Signed the Informed Consent.
* Along with their parent / legal guardian, be capable of comprehending the nature of the study, and be willing and able to adhere to study requirements.
* Along with their parent / legal guardian, agree to maintain the visit schedule .
* Agree to wear allocated contact lenses for a minimum of 5 days per week, at least 6 hours per day on days lenses are worn but not \> 16 hours per day, and to remove lenses at night (i.e., daily wear only with no contact lens wear during sleep), for their duration of the study and to inform the investigator if their schedule is interrupted. Wearing time can be modified by the investigator for health reasons.
* Possess wearable and visually functioning spectacles.
* Be in good general health, based on the parent's / legal guardian's knowledge.
* Have best-corrected high contrast visual acuity based on manifest refraction of 0.10 logMAR (20/25, 6/7.6) or better in each eye.
* Meet the following criteria determined by cycloplegic autorefraction:
* Spherical equivalent between -0.75 to -4.00 D inclusive.
* Astigmatism ≥ -1.00 D.
\*participants who fail astigmatism criterion with autorefraction pass astigmatism criterion if ≥ -0.75 D is measured with subjective refraction.
* anisometropia ≤ 1.00 D.
Exclusion Criteria
* Current or prior use of ANY form of myopia control, including but not limited to:
* Optical devices.
* Bifocal / multifocal spectacles of any type.
* Bifocal / multifocal contact lenses of any type.
* Orthokeratology of any type.
* Pharmacological agents.
* European and Indian sites: Atropine.
* Chinese sites: Atropine with a concentration \> 0.01%. Participants who have previously used 0.01% atropine are eligible for this study provided they agree not to use 0.01% atropine for at least 30 days before baseline and at any time during the study.
* Pirenzepine.
* Participant born earlier than 30 weeks or weighed \< 1500 g at birth.
* Habitual use of a systemic or topical medication that may alter normal ocular findings / is known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and / or during the clinical trial.
* A known allergy to sodium fluorescein, benoxinate, proparacaine, or tropicamide.
* Chinese sites: A known allergy to cyclopentolate.
* A known corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections, or any other recurrent ocular infections.
* Strabismus by cover test at distance (3 m) or near (40 cm) while wearing distance correction under non-cycloplegic conditions.
* Known ocular or systemic disease, such as but not limited to:
* Diabetes.
* Graves' disease.
* Glaucoma.
* Uveitis.
* Scleritis.
* Auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome, and systemic lupus erythematosus.
* Any ocular, systemic, or neuro-developmental conditions that could influence refractive development, such as but not limited to:
* Persistent pupillary membrane.
* Vitreous haemorrhage.
* Cataract.
* Central corneal scarring.
* Eyelid haemangiomas.
* Marfan's syndrome.
* Down's syndrome.
* Ehler's-Danlos syndrome.
* Stickler's syndrome.
* Ocular albinism.
* Retinopathy of prematurity.
* Keratoconus or irregular cornea.
* Biomicroscopic that contraindicate contact lens, such as but limited to:
* Neovascularisation or ghost vessels ≥ 1.5 mm in from limbus.
* Any active anterior segment disease that contraindicates safe contact lens wear.
* Clinically significant giant papillary conjunctivitis.
* Clinically significant abnormalities of the anterior segment, lids, conjunctiva, sclera, or associated structures.
* Allergic or seasonal conjunctivitis if the investigator believes it could significantly interfere with maintaining a specified wearing schedule.
* The investigator may, at their discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant's best interests.
8 Years
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brighten Optix Corporation
UNKNOWN
nthalmic Pty Ltd
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Tilia, MOptom, PhD
Role: PRINCIPAL_INVESTIGATOR
nthalmic Pty Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wenzhou Medical University Eye Hospital
Wenzhou, Lucheng District, China
Tianjin Medical University
Tianjin, Wuqing District, China
Shanghai Fudan University Eye and ENT Hospital
Shanghai, Xuhui District, China
LV Prasad Eye Institute
Hyderabad, Telangana, India
The University of Hyderabad
Hyderabad, Telangana, India
Centre Universitari de la Visió
Terrassa, Barcelona, Spain
Lab. de Superficie Ocular y Lentes de Contacto (SOYLC)
Santiago de Compostela, Galicia, Spain
Ocupharm Research Group (Clinica Universitaria de Optometría), Universidad Complutense Madrid
Madrid, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
nthal2021-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.